Epigenomics taps up Taapken
This article was originally published in Scrip
Epigenomics AG, the German-American cancer molecular diagnostics company, has appointed Dr. Thomas Taapken to serve as acting Chief Executive Officer in addition to his responsibilities as Chief Financial Officer, effective 1 October 2012. Dr Taapken replaces Geert Nygaard who agreed with Epigenomics' supervisory board that he will leave the company effective 30 September, 2012.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.